Clinical and Laboratory ObservationsGolden Bullet—Denosumab Early Rapid Response of Metastatic Giant Cell Tumor of the BoneDemirsoy, Ugur MD; Karadogan, Meriban MD; Selek, Özgür MD; Anik, Yonca MD; Aksu, Görkem MD; Müezzinoglu, Bahar MD; Corapcioglu, Funda MDAuthor Information Departments of *Pediatric Oncology †Orthopaedics and Traumatology ‡Radiology §Radiation Oncology ∥Pathology, Kocaeli University, Umuttepe, 41380 Kocaeli/Turkey The authors declare no conflict of interest. Reprints: Funda Corapcioglu, MD, Department of Pediatric Oncology, Kocaeli University, Umuttepe, 41380 Kocaeli/Turkey (e-mail: [email protected]). Received August 5, 2013 Accepted August 23, 2013 Journal of Pediatric Hematology/Oncology: March 2014 - Volume 36 - Issue 2 - p 156-158 doi: 10.1097/MPH.0000000000000034 Buy Metrics Abstract Giant cell tumor of the bone (GCTB) is usually a benign, locally aggressive tumor with metastatic potential. Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemotherapy regimens. Denosumab, which inhibits RANK-RANKL interaction, is a new, promising actor among targeted therapeutic agents for GCTB. In this report, we emphasize on early rapid response to denosumab in metastatic GCTB. Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.